Looking for a new broker?
Fennec Pharmaceuticals Inc. stock is up 22.18% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 69.23% of the previous 12 December’s closed higher than November.
Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
